Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
(R)-2-Arylpropionamide compounds of formula (I), pharmaceutical preparations of the compounds and a process for making the compounds are described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonuclear leukocytes and monocytes at inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use as inhibitors of chemotaxis of neutrophils and monocytes induced by the C5a fraction of complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of polymorphonuclear leukocytes.
1. A pharmaceutical composition consisting of (R)-2-Aryl-propionamide compound of formula (I)
or a pharmaceutically acceptable salt thereof,
wherein
Ar is a group selected from 4-isobutylphenyl, 2-(2,6-dichloro-phenyl-amino)-phenyl, or a phenyl 3-substituted with a group selected from the group consisting of benzoyl, isopropyl, isobutyl, pent-3-yl, 1-phenylethylen-1-yl, α-methylbenzyl, α-hydroxybenzyl, and α-hydroxyethyl,
R represents hydrogen,
X together with the nitrogen atom of the omega amino group to which it is bound and with the R 1 and R 2 groups forms a non-aromatic nitrogen containing ring selected from 1-methyl-piperydin-4-yl and N-exo-8-methyl-aza-bicyclo[3.2.1.]oct-3-yl;
as the active ingredient in admixture with pharmaceutically acceptable excipients and diluents, wherein the compound of the formula (I) has activity of inhibition of C5a-induced chemotaxis of polymorphonucleate leukocytes and monocytes and is devoid of any significant activity of inhibition of a cyclooxygenase enzyme.
2. A pharmaceutical composition consisting of (R)-2-Aryl-propionamide compound of formula (I)
or a pharmaceutically acceptable salt thereof,
wherein
Ar is a group selected from 4-isobutylphenyl, 2-(2,6-dichloro-phenyl-amino)-phenyl, or a phenyl 3-substituted with a group selected from the group consisting of benzoyl, isopropyl, isobutyl, pent-3-yl, 1-phenylethylen-1-yl, a-methylbenzyl, a-hydroxybenzyl, and a-hydroxyethyl,
R represents hydrogen,
X together with the nitrogen atom of the omega amino group to which it is bound and with the R 1 group forms a non-aromatic nitro en containing 3-7 member monocyclic or polycyclic ring wherein the nitro en atom has a substituent R 2 wherein R 2 represents hydrogen or a C 1 -C 4 alkyl group;
as the active ingredient in admixture with pharmaceutically acceptable excipients and diluents, wherein the compound of the formula (I) has activity of inhibition of C5a-induced chemotaxis of polymorphonucleate leukocytes and monocytes and is devoid of any significant activity of inhibition of a cyclooxygenase enzyme,
wherein said compound of formula (I) is (R)-2-[(4-isobutyl)phenyl]-N—(I-methylpiperidin-4-yl)propionamide; or (R)-2-[(4-isobutyl)phenyl]-N-(exo-8-methyl-8-aza-bicyclo[3.2.1.]oct-3-yl)propionamide.
3. The composition of claim 1 , wherein the composition comprises an additional active compound.
4. The composition of claim 2 , wherein the composition comprises an additional active compound.